Sign up for our Oncology Central weekly news round-up

Combination therapy could boost efficacy for endometrial, colorectal and gastric tumors

Written by Heather Jones, Future Science Group

Researchers from the MD Anderson Cancer Center (TX, USA) have investigated the mechanisms involved in cancer development in tumors caused by mutations in the DNA mismatch repair (MMR) pathway. The study, published in Cancer Cell, reveals a novel therapeutic vulnerability in such tumors and suggests a combined therapy that could improve outcomes in patients with specific cancers.Certain cancers, such as endometrial, colorectal and gastric cancers, can be caused by a mutation-induced underlying loss of MMR function. Their tumors subsequently acquire numerous mutations throughout their DNA that can promote cancer formation. Such cancers can be diagnosed through the detection of genetic...

To view this content, please register now for access

It's completely free